2 assets in Ovarian Squamous Cell Carcinoma

Therapeutic assets addressing Ovarian Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Ovarian Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Ovarian Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)